Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $319.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price raised by Morgan Stanley from $314.00 to $319.00 in a research report report published on Tuesday,Benzinga reports. The firm currently has an overweight rating on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of several other reports. Piper Sandler raised their price target on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Needham & Company LLC boosted their price objective on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, August 26th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research note on Wednesday, August 26th. UBS Group raised their target price on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a “buy” rating in a research report on Friday, September 11th. Finally, Robert W. Baird raised their target price on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $293.45.

Jazz Pharmaceuticals Stock Down 3.1%

Shares of NASDAQ:JAZZ opened at $227.32 on Tuesday. The company has a quick ratio of 1.58, a current ratio of 1.82 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals has a 52-week low of $128.80 and a 52-week high of $266.38. The stock’s fifty day simple moving average is $229.71 and its 200-day simple moving average is $217.40. The company has a market capitalization of $14.59 billion, a P/E ratio of 77.32, a P/E/G ratio of 0.47 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, topping analysts’ consensus estimates of ($4.03) by $0.15. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter last year, the business posted $8.13 EPS. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. As a group, equities research analysts forecast that Jazz Pharmaceuticals will post 10.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bruce Cozadd sold 6,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $215.84, for a total transaction of $1,295,040.00. Following the completion of the transaction, the director owned 339,875 shares of the company’s stock, valued at $73,358,620. This represents a 1.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena Patil sold 1,200 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $240.94, for a total transaction of $289,128.00. Following the transaction, the executive vice president owned 47,671 shares in the company, valued at approximately $11,485,850.74. The trade was a 2.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 101,121 shares of company stock worth $24,858,332 over the last 90 days. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in JAZZ. Triumph Capital Management boosted its position in Jazz Pharmaceuticals by 2.0% during the 2nd quarter. Triumph Capital Management now owns 2,597 shares of the specialty pharmaceutical company’s stock worth $626,000 after purchasing an additional 52 shares during the period. Keybank National Association OH raised its position in Jazz Pharmaceuticals by 0.6% in the third quarter. Keybank National Association OH now owns 10,141 shares of the specialty pharmaceutical company’s stock valued at $2,348,000 after purchasing an additional 57 shares during the period. XML Financial LLC raised its position in Jazz Pharmaceuticals by 1.1% in the third quarter. XML Financial LLC now owns 6,559 shares of the specialty pharmaceutical company’s stock valued at $1,519,000 after purchasing an additional 71 shares during the period. Bessemer Group Inc. raised its position in Jazz Pharmaceuticals by 0.3% in the first quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock valued at $4,228,000 after purchasing an additional 73 shares during the period. Finally, Root Financial Partners LLC lifted its stake in shares of Jazz Pharmaceuticals by 42.8% during the first quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock worth $56,000 after purchasing an additional 89 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat Q3 2026 estimates, reporting revenue of $1.24 billion versus expectations of $1.21 billion, with revenue up 10.4% year over year. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, according to the earnings coverage. Q3 earnings call summary
• Positive Sentiment: Several firms, including RBC, Barclays, Morgan Stanley and JPMorgan, issued bullish commentary or raised price targets after the results, signaling continued analyst confidence. Barclays price target coverage
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares and director Bruce Cozadd sold 6,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans; Galá retained 140,394 shares and Cozadd retained 339,875. Planned sales are less informative about executives’ current views than discretionary transactions. CEO sale filing

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.